Metsera has linked its GLP-1 drug candidate to weight loss of up to 11.3% after 12 weeks, encouraging the biotech to use some ...

Can this diabetes-control breakthrough also become the answer to obesity? From Hollywood’s red carpets to affluent Indians, ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

In a citizen petition posted by the FDA this week, Novo urged the regulator to restrict the ability of compounding pharmacies ...

Expected readouts in diabetes, cancer and depression headline a series of study results that could help the biotechnology ...

GLP-1 drugs — which include Ozempic and its sister drug Wegovy, as well as Mounjaro and Zepbound — mimic at least one hormone produced by the gut to signal fullness, leading to a reduced appetite.

Amidst a race with its competitors to produce the next smash-hit weight loss drug, Novo Nordisk 's ( NVO 0.15%) stock crashed ...

Disappointing trial results for Novo Nordisk A/S’s experimental obesity shot capped a volatile year for investors in drug ...

Pfizer, AstraZeneca, Amgen and several other drug developers aiming to join the weight-loss drug market, which is estimated ...

In the brain, the enzyme ABHD6 degrades a key endocannabinoid molecule known as 2-arachidonoylglycerol (2-AG). Stephanie Fulton, a CRCHUM researcher and professor at Université de Montréal, with David ...

In contrast, HS-10535 is a small molecule drug, which, as the name implies ... as well as sibling medicines like its drug ...